Page header

Position of the Transparency Council – cholestyramine

At its meeting on 7 January 2025, the Transparency Council adopted position No. 3/2025 on the appropriateness of issuing approvals for reimbursement of medicinal products containing the active substance cholestyramine in multiple indications

 

Publication of the position >>